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Background: There has been increasing interest in the use of newer, culture-independent techniques to study the
airway microbiome of COPD patients. We investigated the relationships between the three common potentially
pathogenic microorganisms (PPMs) Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis,
as detected by quantitative PCR (qPCR), and inflammation and health status in stable patients in the London
COPD cohort.
Methods: We prospectively collected sputum, serum and plasma samples for analysis of airway bacterial presence and
load, and airway and systemic inflammation from 99 stable COPD patients between January 2011 and October 2012.
Health status was measured with St George’s Respiratory Questionnaire and COPD Assessment Test.
Results: Airway inflammation and plasma fibrinogen, but not C-reactive protein, were greater in samples with PPM
detection (p < 0.001, p = 0.049 and p = 0.261, respectively). Increasing total bacterial load was associated with increasing
airway (p < 0.01) but not systemic inflammation (p > 0.05). Samples with high total bacterial loads had significantly
higher airway inflammation than both samples without PPM detection and those with lower loads. Haemophilus
influenzae presence was associated with significantly higher levels of airway but not systemic inflammation for all
given pathogen loads (p < 0.05), and was significantly greater than with other PPMs. No association was observed
between inflammation and health status (p > 0.05).
Conclusions: Airway and systemic inflammation, as measured by fibrinogen, is greater in stable COPD patients
with PPMs detected using the culture-independent qPCR technique. The airway, but not systemic inflammatory
response, appears to have a total pathogen-load threshold and appears attributable to Haemophilus influenzae.
However, discordance between inflammation and health status was observed.
Keywords: COPD, Inflammation, Bacteria, ColonisationBackground
Chronic obstructive pulmonary disease (COPD) is char-
acterised by airflow limitation and is associated with
persistent airway and systemic inflammation, which in-
creases during episodes of acute deterioration, known as
exacerbations [1-3]. COPD is currently the third leading
cause of death worldwide [4] and exacerbations contrib-
ute to the substantial morbidity and mortality, and the* Correspondence: richa.singh@imperial.ac.uk
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unless otherwise stated.considerable health-economic burden associated with
this disease [5].
Historically, the tracheobronchial tree and lung paren-
chyma in healthy, non-smoking individuals were described
as sterile, using traditional, culture-based techniques.
However, in COPD patients, potentially pathogenic micro-
organisms (PPMs) are frequently isolated from both
sputum and bronchoscopic samples during periods of
stability, termed lower airway bacterial colonisation
(LABC) [6,7]. Haemophilus influenzae (HI) is often the
most commonly isolated PPM at stable and exacerbation
states, with Streptococcus pneumoniae (SP), and Moraxellatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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detrimental effect on the natural history of COPD, with
increased airway and systemic inflammation [7,10-12], in-
creased exacerbation frequency [6], and an accelerated
lung function decline [13].
Previous LABC studies have used traditional, culture-
based microbiological identification. However, as only
1% of bacteria can be cultured using traditional methods
[14], there has been increasing interest in the use of
culture-independent diagnostic techniques. Many of
these rely on the analysis of the conserved bacterial 16S-
rRNA gene. Studies using such techniques have demon-
strated the presence of a wide range of bacterial species
in healthy individuals, described as the core microbiome,
which may become disrupted in disease states [15].
However, these techniques are expensive and time-
consuming to perform and analyse, limiting their use to
small sample numbers. The culture-independent quanti-
tative polymerase chain reaction (qPCR) technique tar-
geting commonly isolated PPMs in COPD; HI, SP, and
MC, has been shown to be more discriminatory than
culture, detecting a higher prevalence of PPMs at both
stable and exacerbation states [16]. This technique is
relatively inexpensive and can be used to examine much
larger sample numbers.
We hypothesised that using this qPCR technique to
accurately detect PPMs, airway and systemic inflamma-
tion would be related to both their presence and loads,
and that a bacterial load threshold for increased inflam-
mation would be observed, leading to worse health sta-
tus. Furthermore, we hypothesised that as HI tends to
persist in the airways, the higher inflammatory response
seen in colonised patients would be attributable to HI
rather than the other PPMs.
Methods
Patient recruitment
Ninety-nine stable COPD patients enrolled in the London
COPD cohort between January 2011 and October 2012
were included. The patients form part of a rolling cohort
used to prospectively investigate the mechanisms and aeti-
ology of COPD exacerbations [17]. Patients were included
if the post-bronchodilator forced expiratory volume in one
second (FEV1) was ≤80% and FEV1/forced vital capacity
(FVC) was <0.7. As per GOLD guidelines, bronchodilator
reversibility testing was not required for the diagnosis
and assessment of severity [3]. Patients with a history of
asthma, primary bronchiectasis or any other significant re-
spiratory diseases were excluded, as were those unable to
complete daily symptom diary cards.
Clinical assessment
At annual review or recruitment, a full medical and smok-
ing history was taken, clinical examination performedand the SGRQ [18] completed. FEV1 and FVC were mea-
sured in accordance with ATS/ERS guidelines using a
Vitalograph Gold Standard spirometer (Vitalograph Ltd,
Maids Moreton, UK). Body mass index (BMI) was calcu-
lated from height and weight.
Patients completed daily symptom diary cards and
were prospectively reviewed in clinic every three months
when stable. Stable state was defined as those patients
without evidence of symptom-defined exacerbations in
the preceding 4 weeks and the subsequent 2 weeks post-
clinic visit. At all study visits, patients were asked to
complete the CAT. Serum C-reactive protein (CRP) quan-
tification was performed using Modular Analytics E 170
Module (Roche, Burgess Hill, UK) and plasma fibrino-
gen measured using the Clauss method (IL ACL Top
Coagulation Analyzer, Lexington, MA, USA).
Sputum collection and processing
Patients were asked to spontaneously expectorate spu-
tum samples into a sterile pot. Patients unable to
spontaneously expectorate sputum underwent sputum
induction [19]. Sputum samples were graded using the
BronkoTest® colour chart and processed as soon as
possible following collection.
Sputum plugs were separated from contaminating sal-
iva by macroscopic examination using sterile forceps.
The sputum was homogenized with standard isotonic
phosphate-buffered saline (PBS) with glass beads as pre-
viously published [2,20]. A proportion of this prepar-
ation was frozen at -80°C and used for later detection of
PPMs by qPCR; the remainder was centrifuged and ali-
quots of supernatant stored at -80°C for subsequent ana-
lysis of airway cytokines.
Routine microbiological culture
Where there was sufficient sputum quantity, one-third
was taken for subsequent routine microbiological culture
carried out in the Department of Medical Microbiology,
Royal Free Hampstead NHS Trust, London, as previously
described [16].
DNA extraction and multiplex qPCR detection of bacteria
qPCR was carried out in the Centre for Clinical Micro-
biology, University College London, as previously de-
scribed [16]. Homogenized sputum samples were thawed
and processed using a heat-kill treatment at 90°C for
30 minutes before being centrifuged at 13 000 g for
10 minutes. The cell pellet was washed in 1 ml PBS and
spun at 13 000 g for another 10 minutes before removal
of the supernatant and re-suspension of the pellet in
200 μl of PCR-grade UV-sterilized water (Sigma-W4502).
200 μl of 10% Chelex 100 (Sigma C-7901) was added to
each sample and incubated for 20 minutes in a heat block
at 56°C. Samples were heated at 95°C for five minutes
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were spun in a microfuge at 16 000 g for 10 minutes.
Supernatant containing extracted DNA was transferred
to a fresh UV-sterilized 1.5 ml eppendorf tube and stored
at 4°C.
Real-time multiplex qPCR was performed on the ex-
tracted DNA for SP, HI and MC as previously described
[16]. The minimum limit of detection used in this study
was 104 colony-forming units (cfu).ml-1. Samples were
classified to have lower airway bacteria colonisation
(LABC) if the qPCR was positive for at least one of these
three PPMs.
Measurement of sputum inflammatory markers
Levels of CXC-chemokine ligand 8 (CXCL8), interleukin
(IL)-1β, and myeloperoxidase (MPO) in the sputum
supernatants were measured using high sensitivity
enzyme-linked immunosorbent assay kits (R&D Systems,
Abingdon, UK). The lower limit of detection were
3.5 pg.ml-1, <1.0 pg.ml-1 and 0.014 ng.ml-1 for CXCL8,
IL-1β, and MPO respectively.
Statistical analysis
Data were analysed using GraphPad PRISM version 6.0
(GraphPad Software Inc., San Diego, CA, USA) and
PASW Statistics version 21 (SPSS Inc., Chicago, IL,
USA). Normally distributed data were expressed as mean
and standard deviation (SD) and non-parametric data
as median and interquartile range (IQR). Differences
between groups were analysed by independent t-test,
Mann-Whitney U Test, paired t-test, Wilcoxon-matched
pairs, one-way ANOVA or Kruskal-Wallis analysis with
multiple comparisons, depending on the sample popu-
lation being investigated. Sputum cytokines and bac-
terial load by qPCR were correlated using Spearman’s
rank correlation (two-tailed) in a univariate analysis.
Relationship between PPM load, PPM species and spu-
tum cytokines were analyzed by multiple regression.
Relationship between sputum cytokines, exacerbation
frequency, FEV1 %predicted and SGRQ or CAT score were
analyzed by linear regression in a multivariate analysis.
Categorical binary variables were analyzed by χ2-analysis.
A probability of p < 0.05 was considered to be statistically
significant.
Sample colonisation status was considered as indi-
vidual events when describing the relationship to in-
flammation, as the associated PPMs (HI, SP or MC)
could differ within the same individual and only cross-
sectional analyses were performed. When colonisation
status was related to patient characteristics, only the
first sample was used from each patient to avoid com-
plications with repeated measures. SGRQ and CAT
scores were analyzed with inflammatory markers taken
on the same day.Ethical considerations
The study was approved by the Royal Free Hospital Re-
search Ethics Committee (09/H0270/8). All patients gave
written informed consent.
Results
Patient characteristics
Ninety-nine COPD patients provided 183 sputum samples
for analysis. Their baseline characteristics are reported in
Table 1. Patients were sub-grouped into colonised (LABC)
and non-LABC based on their sputum sample at study re-
cruitment. There were no significant differences in baseline
characteristics between the two groups.
Sputum bacterial isolates and loads
One or more PPMs were identified by qPCR in 64/183
(35%) of sputum samples and these samples were defined
as LABC. Single HI or SP isolation was equally prevalent,
each identified in 21/64 (33%) of positive samples. Mixed-
PPM detection (>1 PPM) was identified in 15/64 (23%) of
samples, and single MC detected in 7/64 (11%).
The mean bacterial load for all PPMs was 107.1(SD1.7)
cfu.ml-1. The bacterial loads detected for individual HI,
SP, MC, and mixed-PPM isolates were significantly dif-
ferent (106.2(1.2) vs. 106.5(1.1) vs. 108.6(1.8) and 108.5(1.5)
cfu.ml-1 respectively, p < 0.001). When each species load
was compared, HI and SP loads were similar to each other
(p > 0.05) but were both significantly lower than MC and
mixed-PPM loads (all, p < 0.001).
Qualitative bacterial culture, in addition to qPCR data,
was available in 116/183 (63%) samples where sufficient
sputum was obtained. Of these, 17/116 (11%) samples
had PPMs identified on culture; 7 HI, 1 MC, 5 SP, 2
Pseudomonas aeruginosa, 1 Staphylococcus aureus and 1
Proteus vulgaris, compared to 45/116 (39%) samples
which had PPMs identified by qPCR (χ2, p < 0.001).
Bacterial colonisation status and BronkoTest® colour
172/183 (94%) sputum samples had colour recorded
using the standardised BronkoTest® chart. The propor-
tion of LABC samples for any PPM identified by qPCR
was significantly higher with darker (higher BronkoTest®
number) sputum (χ2, p = 0.001, Figure 1A). In 57/64
(89%) LABC samples where colour was recorded, in-
creasing total bacterial load was significantly associated
with higher BronkoTest® colour (rho = 0.39; p = 0.003,
Figure 1B), but no significant difference was seen be-
tween BronkoTest® colour and the isolation of the differ-
ent PPMs (p = 0.817).
Bacterial colonisation and inflammation
LABC samples had significantly higher levels of spu-
tum CXCL8, IL-1β and MPO than non-LABC samples
(p < 0.001, Table 2).
Table 1 Clinical characteristics of stable COPD patients, and by colonisation status* at study onset
Overall Non-colonised Colonised p-value†
n = 99 n = 64 n = 35
Mean (SD) Mean (SD) Mean (SD)
Age (years) 72.1 (8.9) 72.0 (9.3) 72.0 (9.3) 0.947
FEV1 (L) 1.32 (0.54) 1.36 (0.59) 1.24 (0.44) 0.318
FEV1 (% predicted) 51.5 (21.6) 53.3 (21.7) 48.1 (21.4) 0.257
FVC (L) 2.80 (0.86) 2.84 (0.93) 2.74 (0.73) 0.607
FEV1 / FVC ratio (%) 47.2 (13.0) 48.0 (13.4) 45.9 (12.3) 0.440
BMI (kg/m2) 26.6 (5.8) 26.9 (5.8) 26.2 (5.8) 0.591
Median (IQR) Median (IQR) Median (IQR)
Exacerbation frequency 2.00 (1.00-3.00) 1.97 (1.04-3.03) 2.04 (1.00-2.89) 0.511
Smoking pack years 48.4 (24.4-67.5) 47.2 (25.4-64.7) 51.0 (25.4-105.6) 0.213
ICS dose (beclomethasone equivalent μg) 1000 (500-2000) 1000 (500-2000) 1000 (500-2000) 0.224
N (%) N (%) N (%)
Male gender 66 (67) 40 (63) 26 (74) 0.234
Current Smokers 34 (34) 23 (36) 11 (31) 0.651
Chronic Bronchitis 78 (79) 49 (77) 29 (83) 0.464
*Bronchial colonisation defined as sputum positive for Haemophilus influenzae (HI), Streptococcus pneumoniae (SP) and/or Moraxella catarrhalis (MC) using quantitative
polymerase chain reaction (qPCR).
Definitions: ICS = inhaled corticosteroids; BMI = body mass index.
†p-value refers to unpaired t-test between non-colonised and colonised patients.
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with increasing CXCL8, IL-1β and MPO (rho = 0.44;
p < 0.001, rho = 0.45; p < 0.001, and rho = 0.32; p = 0.011
respectively, Figure 2). All airway cytokines significantly
correlated with each other (rho > 0.60; p < 0.001). There
were no significant associations between airway cytokines
and clinical demographics including FEV1 %predicted,
exacerbation frequency, smoking status or pack year his-
tory (PYH), or inhaled corticosteroid use and dose (all
p > 0.05, Additional file 1: Table S1).
Using the previously proposed bacterial load-inflammatory
threshold of 107 cfu.ml-1 [10], LABC samples were
sub-grouped into low total bacterial loads (≤107.0 cfu.ml-1,Figure 1 Bacterial colonisation status and BronkoTest® colour. (A) Pro
to BronkoTest® colour chart. (B) Relationship between BronkoTest® colour an = 32) and high total bacterial loads (>107.0 cfu.ml-1,
n = 32) and compared with non-LABC samples. There
was a significant difference between the three groups
for all airway cytokines (p < 0.001). When each group
was compared with each other, airway cytokines levels
were similar between the non-LABC and low total bac-
terial load groups, but the high total bacterial load had
significantly higher airway cytokines levels than both of
these groups (Figure 3), suggesting a possible bacterial
load threshold for increased airway inflammation.
Plasma fibrinogen was significantly higher in LABC
samples than in non-LABC samples (3.8 (3.3-4.4) vs.
3.5 (3.2-4.1) g.l-1, p = 0.049, Table 2). There was noportion of colonised (LABC) and non-LABC sputum samples according
nd total bacterial load by qPCR.
Table 2 Airway and systemic inflammation in colonised*
and non-colonised samples
Non-colonised
samples
Colonised
samples
p-value
n = 119 n = 64
Median (IQR) CXCL8 (ng.ml-1) 83 (24-182) 162 (71-309) <0.001
Median (IQR) IL-1β (ng.ml-1) 0.6 (0.2-1.9) 1.4 (0.7-5.9) <0.001
Median (IQR) MPO (μg.ml-1) 17.1 (7.6-30.6) 29.5 (16.2-40.9) <0.001
Median (IQR) CRP (mg.l-1) 2.0 (1.0-8.0) 2.0 (1.0-5.0) 0.261
Median (IQR) Fibrinogen (g.l-1) 3.5 (3.2-4.1) 3.8 (3.3-4.4) 0.049
*Bronchial colonisation defined as sputum sample positive Haemophilus
influenzae (HI), Streptococcus pneumoniae (SP) and/or Moraxella catarrhalis (MC)
using quantitative polymerase chain reaction (qPCR).
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and LABC samples (2.0 (1.0-5.0) vs. 2.0 (1.0-8.0) mg.l-l,
p = 0.261, Table 2).
Species-specific inflammatory responses
There was a significant difference in airway CXCL8, IL-
1β and MPO between the samples with single isolation
of of HI (n = 21), SP (n = 21) or MC (n = 7) and mixed-
PPM (n = 15) colonised samples (p = 0.003, p < 0.001,
and p = 0.011 respectively, Table 3). Despite similar
bacterial loads in HI- and SP-colonised samples, and
higher bacterial loads in MC- and mixed-PPM-colonised
samples, CXCL8 was significantly higher only in HI-
colonised samples compared to non-LABC samples (179
(95-453) vs. 83 (24-182) ng.ml-1, p < 0.001, Figure 4A).
Furthermore, IL-1β and MPO levels were significantly
higher in HI-colonised samples compared to non-LABC
samples (4.8 (0.8-7.8) vs. 0.6 (0.2-1.9) ng.ml-1, p < 0.001
Figure 4B; 30.1 (26.4-38.9) vs. 17.1 (7.6-30.6) μg.ml-1,
p < 0.05 Figure 4C).
Mixed-PPM samples also had significantly higher
IL-1β level than non-LABC samples (1.6 (0.9-6.7) vs.
0.6 (0.2-1.9) ng.ml-1, p < 0.05, Figure 4B). However,
despite a higher total bacterial load in mixed-PPM
colonised samples compared to HI-colonised samples, noFigure 2 Relationship between total bacterial load, as measured by q
(C) MPO.significant augmentation of airway inflammatory responses
was seen.
Adjusting for the different PPMs loads, HI-colonised
samples were associated with significantly higher CXCL8,
IL-1β and MPO response than individual SP or MC-
colonised and mixed-PPM-colonised samples (p < 0.001,
p < 0.001, and p = 0.002 respectively, Figure 5).
There were no species-specific differences in systemic
inflammation as measured by serum CRP (p = 0.879) or
plasma fibrinogen (p = 0.587).
Bacterial colonisation and health status
74 SGRQs and 113 CAT scores were available with
paired sputum samples. No significant association was
observed between SGRQ or CAT scores with either air-
way or systemic inflammation in a univariate analysis or
in a multivariate analysis taking into account FEV1 % pre-
dicted and exacerbation frequency (all, p > 0.05). There
was no significant difference between total SGRQ and
CAT scores in non-LABC and LABC samples (p > 0.05).
Discussion
This is the first study to date to examine and validate
the relationship between inflammation and airway PPM
presence, load and species-effects using the culture-
independent qPCR technique in a well-characterised cohort
of stable COPD patients. We have demonstrated that the
presence of sputum PPMs are associated with increased air-
way and systemic, as measured by fibrinogen, inflammatory
response compared to samples without PPM detection. In-
creasing total bacterial load was associated with higher
levels of airway but not systemic inflammation and import-
antly, we report an apparent inflammatory threshold. In
addition, we have demonstrated a species-specific inflam-
matory response, with HI presence associated with sig-
nificantly higher airway inflammatory response for all
pathogen loads. However, there was discordance between
health status and the airway inflammatory response.
Increasing qPCR total bacterial load was strongly asso-
ciated with an increase in airway but not systemicPCR, in colonised samples (n = 64) and (A) CXCL8, (B) IL-1β, and
Figure 3 Inflammatory thresholds of (A) CXCL8, (B) IL-1β, and (C) MPO. Low load samples were defined as a total bacterial load
of ≤107.0 cfu.ml-1 (n = 32) and high load as >107.0 cfu.ml-1 (n = 32). LABC = lower airway bacterial colonisation.
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colour which acts as a surrogate for MPO levels [21].
Importantly we have demonstrated an apparent total
bacterial load threshold, above which airway inflammation
is significantly higher than in samples without PPMs
detected, or in those with lower loads, consistent with pre-
vious culture-based studies [10]. Detailed microbiomic
studies in healthy, non-smoking individuals have demon-
strated that a core pulmonary bacterial community exists
which may include PPMs at low loads [15], and hence the
detection of PPMs alone may not be pathological.
There is a long-standing debate as to the meaning of
the term ‘colonisation’ [22]. This terminology suggests a
benign process and one without host-pathogen interac-
tions and consequences, which are key to the definition
of infection. The importance of using a bacterial load
threshold which is associated with a greater inflamma-
tory response is that this avoids using purely the detec-
tion of a PPM to define colonisation, and thus enabling
a more accurate definition which reflects the clear in-
flammatory consequences at higher bacterial loads. In
this respect, it may be more appropriate to use the term
‘colonisation’ when PPMs are present, but in low loads
and without inflammatory consequence, and ‘chronicTable 3 Bacterial loads and associated airway inflammation in
(PPMs) colonised samples
HI SP
n = 21 n = 21
Mean (SD) Bacterial load 106.2(1.2) 106.5(1.1)
Median (IQR) CXCL8 (ng.ml-1) 179 90
(95-453) (50-194)
Median (IQR) IL-1β (ng.ml-1) 4.8 0.9
(0.8-7.8) (0.6-1.5)
Median (IQR) MPO (μg.ml-1) 30.1 27.2
(26.4-38.9) (13.3-37.
Definitions: HI = Haemophilus influenzae; SP = Streptococcus pneumoniae; MC =Morax
†p-value refers to One-way ANOVA or Kruskal-Wallis between the single PPMs andairway infection’ when there are higher pathogen loads
associated with a greater inflammatory response. We de-
fined the threshold-effect using previous inflammatory
data based on bacterial loads determined by culture [10].
However to date, there have been no direct comparisons
of bacterial loads as measured by both culture and
culture-independent microbiological techniques, and
hence the bacterial load threshold measured by qPCR was
an arbitrary measure. In our study, the colonised sample
size may be underpowered to study this phenomenon in
detail, and in particular with respect to the different PPMs.
Therefore, further research is needed to investigate the
presence of such a bacterial load threshold, using larger
data sets, and different microbiological techniques, and to
determine how different bacterial loads may affect this
inflammatory threshold.
Systemic inflammation, as measured by fibrinogen but
not CRP, was significantly higher in samples with PPMs
detected than in those without, although the absolute
difference was small. No relationship was observed be-
tween either total bacterial load or species-specific loads
and systemic inflammation. The majority of previous stud-
ies investigating inflammatory response in stable COPD
patients have focused on airway rather than systemicsingle and mixed-potentially pathogenic microorganisms
MC mixed-PPM p-value†
n = 7 n = 15
108.6(1.8) 108.5(1.5) <0.001
219 127 0.003
(140-309) (67-677)
1.4 1.6 <0.001
(0.4-7.2) (0.9-6.7)
23.6 29.1 0.011
6) (18.1-35.6) (11.1-51.0)
ella catarrhalis; PPM = potentially pathogenic microorganisms.
mixed-PPM samples.
Figure 4 The species-specific effect of potentially pathogenic microorganisms (PPMs) on (A) CXCL8, (B) IL-1β, and (C) MPO. LABC = lower
airway bacterial colonisation; HI = Haemophilus influenzae; SP = Streptococcus pneumoniae; MC =Moraxella catarrhalis; mixed =mixed potentially
pathogenic microorganisms.
Figure 5 Multiple regression analysis showing change in (A) CXCL8, (B) IL-1β, and (C) MPO in relation to the bacterial load of single isolate
Haemophilus influenzae (HI, n = 21), Streptococcus pneumoniae (SP, n = 21) and Moraxella catarrhalis (MC, n = 7) and mixed-potentially
pathogenic microorganisms (PPMs) (mixed, n = 15) samples.
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has been measured in patients with PPM detection, the
evidence for raised fibrinogen and CRP has been con-
flicting, and no clear association has been found with
bacterial loads [7,12]. However, systemic inflammation,
and in particular raised fibrinogen, has been sug-
gested as a possible link between COPD and associated
cardiovascular events [23] and also as a potential bio-
marker to identify patients with a higher risk of mortality
[24]. Therefore, the role of fibrinogen in the pathogenesis
and clinical outcomes in COPD patients with bacterial col-
onisation is important area of research for future studies.
We demonstrated greater airway inflammation for all
measured cytokines appears to be attributable to HI ra-
ther than other PPMs. Species-specific effects on airway
inflammation have been alluded to in an in vitro study
of MC [25], and also with HI in culture-based in vivo
studies of patients with chronic bronchitis [10] and in
stable COPD patients with HI colonisation [12]. How-
ever, these studies did not take into account the different
pathogen loads. We have demonstrated that individual
pathogens and mixed-PPM samples had significantly
different loads, and at all bacterial loads, airway CXCL8,
IL-1β, and MPO were significantly higher for HI.
HI is often the most prevalent PPM cultured at stable
state in COPD patients [6,11-13], and a key mechanism in
its pathogenesis is its ability to adhere to the already dam-
aged epithelium of the lower respiratory tract in COPD pa-
tients [26], and some studies have demonstrated that HI
may reside between the epithelial and subepithelial tissues
[27], evading mucosal immunity and worsening the under-
lying airway inflammation seen in COPD.
There was evidence in this study of discordance be-
tween inflammation and health status as measured by
the SGRQ and CAT scores, and therefore targeting in-
flammation alone may not necessarily improve health
status. However, a recent longitudinal study by Desai
and colleagues demonstrated that daily symptoms, as
measured by the Breathlessness, Cough and Sputum
Scale (BCSS), were significantly higher during periods of
colonisation compared to periods without [28]. PPM iso-
lation in stable COPD has been shown to be associated
with an increased exacerbation frequency [6] and faster
decline in FEV1 % predicted [13], both of which contrib-
ute significantly to health status [17]. Therefore, the lack
of correlation between quality of life and colonisation in
our study compared to the study by Desai and colleagues
may be explained by the longitudinal nature of their
study and different heath status questionnaires used.
Further longitudinal studies are warranted to determine
whether these important clinical outcomes are also
species-specific, and thus whether targeting stable HI
isolation by using long-term antibiotics or vaccination
would provide clinical benefit.PPM detection during stable COPD appears to be dy-
namic, with patients changing their colonisation status
and which species, strain and load of PPMs are isolated,
likely to result in waxing and waning of airway inflamma-
tion [13,29-31]. This study was limited to cross-sectional
analysis, with lower airway bacterial colonisation defined
as being a single positive sputum sample. The inflamma-
tory responses to bacterial loads as measured by molecu-
lar techniques have not been previously reported, but in
view of the high diagnostic yield of this qPCR technique
compared to culture, further studies exploring this
dynamic process are likely to use similar techniques, and
therefore the relationship between load and inflammation
must first be explored. Unlike in other respiratory dis-
eases, such as cystic fibrosis, where multiple positive spu-
tum samples are required before patients are classified as
‘colonised’, there has been no such consensus in COPD
research studies. Thus, further longitudinal studies must
aim to address this key question as to whether single or
multiple positive sputum samples define colonisation, so
appropriate patients can be targeted for clinical trials.
Although qPCR may detect both viable and non-viable
bacteria, a clear relationship between bacterial DNA load
and airway inflammation is demonstrated. While this
qPCR technique does not detect PPMs other than HI, SP,
or MC, the corresponding routine culture data showed
that only 2% of sputum samples had evidence of a PPM
other than those that are able to be detected by this tech-
nique. However, routine bacterial culture only reports
PPMs with a bacterial load greater than 105 cfu/ml, and
therefore some patients who were determined to be non-
colonised, may indeed have PPMs present at stable state,
contributing to the total bacterial load. Although total bac-
terial loads, as measured by quantitative bacterial culture
and culture-independent techniques, such as 16S, are able
to detect both recognised respiratory pathogens and com-
mensal bacteria, these techniques also have recognised
limitations. Quantitative culture has the inherent inaccur-
acy of visual interpretation of colony counts, and the inter-
action between non-respiratory pathogens, included in the
total bacterial load as measured by 16S, and inflammation
is not well characterised. However, despite these limita-
tions, the high diagnostic yield of this qPCR technique
highlights the strength of this technique and its po-
tential utility in the clinical practice of microbiological
study.
A further limitation in our study is that co-existing
bronchiectasis was not assessed by CT scanning, al-
though no patients had evidence of clinical bronchiec-
tasis. Previous studies report up to 50-60% of stable
COPD have radiological evidence of bronchiectasis, al-
though these changes were generally mild [32,33]. Second-
ary bronchiectasis may be more likely in COPD patients
with airway PPM isolation as a result of the vicious cycle of
Singh et al. Respiratory Research 2014, 15:114 Page 9 of 10
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thus the availability of CT scans would be unlikely to alter
the important findings from this study.
In conclusion, using the high diagnostic yield of
qPCR to identify airway PPMs and their loads, we have
demonstrated that the airway, but not systemic inflam-
matory response, appears to have an inflammatory
threshold and is significantly higher with HI presence.
Further observational and interventional evidence is
required to understand the nature and significance of
dynamic changes in HI and other PPMs.
Additional file
Additional file 1: Table S1. Relationships between airway inflammation
and clinical demographics from 99 stable COPD patients*.
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